CLIA Waived 15 panel urine drug test FEN, NFYL, EDDP

CLIA Waived 15 Panel Urine Drug Test Dip Card – Professional-Grade, Fast & Accurate Results

Ensure complete and confident drug screening with our CLIA Waived 15 Panel Urine Drug Test Dip Card—engineered for accuracy, ease of use, and fast results in medical, workplace, or at-home settings. This high-performance diagnostic tool offers broad detection of both commonly abused drugs and high-risk prescription substances from a single urine sample.

With a total of 15 drug panels, including critical substances like Fentanyl (FEN), Norfentanyl (NFYL), EDDP, and Oxycodone, this 15 panel urine drug test delivers comprehensive coverage with precise cutoff levels that align with clinical and occupational testing standards.

Whether you’re a healthcare professional, treatment provider, employer, or individual, this CLIA Waived 15 panel urine drug test provides a reliable, cost-effective solution for detecting drug use quickly and effectively.

15 panel drug test list:

🔍 What Is the CLIA Waived 15 Panel Urine Drug Test?

The 15 panel urine drug test is a professional-grade diagnostic device designed to detect 15 different drugs and their metabolites in human urine. With a CLIA waiver, it meets Clinical Laboratory Improvement Amendments (CLIA) guidelines, allowing it to be used in physician offices, labs, outpatient facilities, and even non-laboratory environments like workplace testing programs.

Each test is self-contained, requiring no additional equipment, electricity, or lab processing—simply dip the test into a urine sample and read the results in 5 minutes.

✅ Key Features

• CLIA Waived & FDA 510(k) Cleared – Safe and approved for professional and clinical environments
• Detects 15 Substances – Includes high-risk opioids like Fentanyl and its metabolite Norfentanyl
• Accurate and Reliable – Lab-grade quality with results in under 5 minutes
• Simple to Use – Just dip and read, with no instrumentation or special training required
• Individually Wrapped – Each dip card is sealed to ensure sterility and long shelf life
• Shelf Life – Up to 24 months when stored at room temperature
• Tamper-Evident Packaging – Ensures test integrity and reliability
• Compact and Portable – Ideal for remote testing, fieldwork, or point-of-care use

👩‍⚕️15 panel urine drug test are Ideal For:

• Occupational Health Programs – For pre-employment, random, or post-accident screening
• Clinical Testing – Pain management, behavioral health, addiction treatment
• Substance Abuse Recovery Monitoring
• Parole and Probation Drug Testing
• Schools and Athletic Organizations
• Rehabilitation Clinics
• Home Use – For private and confidential self-screening

📦 Product Specifications

• Product Name: 15 panel urine drug test Dip Card – CLIA Waived
• Test Panels: 15 drug classes
• Methodology: Lateral Flow Immunoassay
• Results Time: 5 minutes
• Storage Temperature: 36°F – 78°F (2°C – 25°C)
• Shelf Life: 24 months from manufacturing date
• Package Includes: Individually wrapped dip cards

🛡️ Why Choose This 15 Panel Dip Test?

Our CLIA Waived 15 panel drug test is manufactured under strict quality control protocols to ensure consistency, reliability, and accuracy. It’s a perfect balance of cost-efficiency and thoroughness, allowing for high-volume testing without sacrificing performance.

This test is particularly effective in detecting prescription opioid misuse, with panels for Oxycodone, Fentanyl, Methadone and its metabolite EDDP, Buprenorphine, and Norfentanyl—making it one of the most comprehensive point-of-care tests available.

💊 Deeper Insight into EDDP and Norfentanyl Detection

🔬 Why EDDP Matters (Methadone Metabolite)

EDDP (2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine) is a primary metabolite of Methadone, a synthetic opioid commonly used in medication-assisted treatment (MAT) for opioid addiction. Standard drug tests that only screen for Methadone may miss the metabolite, especially if Methadone has been metabolized completely in the body.

By including EDDP at a cutoff level of 300 ng/mL, this 15 panel drug test ensures that you capture accurate data on Methadone use—even when only its metabolite remains present in the urine. This is particularly important in:

• Addiction recovery programs
• Probation or parole testing
• Pain management clinics
• MAT compliance monitoring

With the inclusion of both Methadone (MTD) and EDDP, this test provides a complete picture of Methadone administration, helping professionals distinguish between proper use, non-use, or tampering.

🧬 Why Norfentanyl Detection Is Crucial

Norfentanyl is the primary metabolite of Fentanyl, a synthetic opioid that is 50–100 times more potent than morphine. As Fentanyl abuse rises sharply in many parts of the world, detecting only the parent drug is often insufficient. Many individuals metabolize Fentanyl quickly, leaving only Norfentanyl present in the urine.

This CLIA Waived 15 panel drug test urine screens for Norfentanyl at a sensitive cutoff of 5 ng/mL, enhancing detection accuracy. Combined with a Fentanyl (FEN) panel at 1 ng/mL, this test ensures high sensitivity to:

• Recent Fentanyl use
• Delayed metabolite presence
• Tampering or substitution attempts

This dual-detection method helps confirm Fentanyl exposure more reliably than tests that only check for the parent drug. Norfentanyl screening is especially critical for:

• Emergency rooms and overdose triage
• High-risk workplaces (construction, transportation, security)
• Law enforcement and court-ordered programs
• Rehabilitation facilities treating opioid dependence